drugset / Trial / NCT00058838

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

NCT00058838

Phase 3 Completed 854 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease

Timeline

Start
2003-04
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject sumanirole Small molecule

Indications